Correction: IL‑6‑mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL‑6 receptor‑alpha and activation of STAT3/NRF2 pathway.

IF 9.4 1区医学 Q1 HEMATOLOGY

Experimental Hematology & Oncology Pub Date : 2025-05-31 DOI:10.1186/s40164-025-00671-2

Amani Hassan, Tenzin Kungyal, Shufeng Zhou, Meryem Blati, Kenneth Finnson, Nick Bertos, Nahid Golabi, Nader Sadeghi, Sampath Loganathan, Anie Philip

引用次数: 0

查看原文本刊更多论文

更正：鳞状细胞癌细胞中IL - 6介导的致瘤性和抗氧化状态是由CD109通过IL - 6受体α的稳定和STAT3/NRF2通路的激活来驱动的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental Hematology & Oncology Medicine-Oncology

CiteScore

12.60

自引率

7.30%

发文量

审稿时长

6 weeks

期刊介绍： Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.